Co-targeting EGFR and IKKβ/NF-κB signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell cancer. [electronic resource]
Producer: 20191112Description: 306-316 p. digitalISSN:- 1532-1827
- Animals
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Drug Resistance, Neoplasm -- drug effects
- ErbB Receptors -- antagonists & inhibitors
- Erlotinib Hydrochloride -- administration & dosage
- Gefitinib -- administration & dosage
- Gene Expression Regulation, Neoplastic -- drug effects
- Humans
- I-kappa B Kinase -- antagonists & inhibitors
- Mice
- NF-kappa B -- genetics
- Oxazines -- pharmacology
- Protein Kinase Inhibitors -- administration & dosage
- Pyridines -- pharmacology
- Receptor, ErbB-2 -- genetics
- Receptor, ErbB-3 -- genetics
- Signal Transduction -- drug effects
- Squamous Cell Carcinoma of Head and Neck -- drug therapy
- TOR Serine-Threonine Kinases -- genetics
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.